GlassScriptPhysician profile
Ramachandra Tata
NPI 1962485482
$5,918.50
in general payments reported to CMS, 2019-2025
51 companies · $305 in 2025
The $305 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,541 · 2020: $1,646 · 2021: $883 · 2022: $379 · 2023: $595 · 2024: $569 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,456 · Education: $13.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,456.42 |
| Education | $13.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $539.12 | 2019-2025 | |
| Ucb, INC. | $473.31 | 2019-2025 | Rystiggo, Zilbrysq |
| Lundbeck LLC | $395.25 | 2019-2024 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $372.42 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $281.05 | 2019-2025 | Ultomiris |
| Biogen, INC. | $241.97 | 2019-2024 | Skyclarys |
| Mdd US Operations, LLC | $213.79 | 2019-2021 | |
| Abbvie INC. | $212.81 | 2020-2025 | |
| Genentech USA, INC. | $207.04 | 2019-2024 | Ocrevus |
| Amgen INC. | $180.59 | 2019-2024 | Uplizna |
| Allergan, INC. | $167.52 | 2019-2022 | |
| Sk Life Science, INC. | $133.27 | 2020-2024 | Xcopri |
| Eisai INC. | $132.40 | 2020-2025 | |
| Emd Serono, INC. | $126.67 | 2019-2021 | |
| Grifols USA, LLC | $126.23 | 2019-2024 | Gamunex-C |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramachandra Tata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.